Financhill
Sell
24

BUDZ Quote, Financials, Valuation and Earnings

Last price:
$0.03
Seasonality move :
-22.27%
Day range:
$0.03 - $0.03
52-week range:
$0.03 - $0.07
Dividend yield:
0%
P/E ratio:
180.00x
P/S ratio:
--
P/B ratio:
887.06x
Volume:
12.1K
Avg. volume:
26.3K
1-year change:
-60%
Market cap:
$4.1M
Revenue:
--
EPS (TTM):
-$0.01

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
BUDZ
Weed
-- -- -- -- --
CAH
Cardinal Health
$59.5B $2.15 1.61% 104.13% $169.87
COR
Cencora
$84.6B $3.81 8.21% 57.22% $321.50
LAB
Standard BioTools
$40.9M -$0.04 7.07% -66.67% $2.38
MCK
McKesson
$103.7B $8.74 20.2% 18.43% $758.57
PNPL
Pineapple
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
BUDZ
Weed
$0.03 -- $4.1M 180.00x $0.00 0% --
CAH
Cardinal Health
$161.41 $169.87 $38.5B 25.18x $0.51 1.25% 0.18x
COR
Cencora
$295.54 $321.50 $57.3B 34.29x $0.55 0.73% 0.19x
LAB
Standard BioTools
$1.05 $2.38 $379.3M -- $0.00 0% 2.32x
MCK
McKesson
$728.20 $758.57 $91B 28.19x $0.71 0.39% 0.26x
PNPL
Pineapple
$0.1200 -- $8.8M -- $0.00 0% 58.98x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
BUDZ
Weed
-- -0.348 -- --
CAH
Cardinal Health
162.31% 0.623 22.64% 0.44x
COR
Cencora
88.58% 0.187 14.53% 0.48x
LAB
Standard BioTools
0.07% -0.784 0.07% 5.22x
MCK
McKesson
157.93% 0.622 6.69% 0.51x
PNPL
Pineapple
-- 6.058 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
BUDZ
Weed
-- -$434.7K -- -- -- -$71.8K
CAH
Cardinal Health
$2.1B $656M 46.27% -- 1.35% $2.8B
COR
Cencora
$3.1B $1.2B 24.2% 183.42% 1.41% $3.2B
LAB
Standard BioTools
$19.7M -$30.3M -24.87% -26.52% -64.18% -$35.3M
MCK
McKesson
$3.6B $1.7B 79.77% -- 1.72% $7.5B
PNPL
Pineapple
-- -- -- -- -- --

Weed vs. Competitors

  • Which has Higher Returns BUDZ or CAH?

    Cardinal Health has a net margin of -- compared to Weed's net margin of 0.92%. Weed's return on equity of -- beat Cardinal Health's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BUDZ
    Weed
    -- -$0.00 --
    CAH
    Cardinal Health
    3.87% $2.10 $5.8B
  • What do Analysts Say About BUDZ or CAH?

    Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Cardinal Health has an analysts' consensus of $169.87 which suggests that it could grow by 5.24%. Given that Cardinal Health has higher upside potential than Weed, analysts believe Cardinal Health is more attractive than Weed.

    Company Buy Ratings Hold Ratings Sell Ratings
    BUDZ
    Weed
    0 0 0
    CAH
    Cardinal Health
    10 4 0
  • Is BUDZ or CAH More Risky?

    Weed has a beta of 0.654, which suggesting that the stock is 34.592% less volatile than S&P 500. In comparison Cardinal Health has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.915%.

  • Which is a Better Dividend Stock BUDZ or CAH?

    Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cardinal Health offers a yield of 1.25% to investors and pays a quarterly dividend of $0.51 per share. Weed pays -- of its earnings as a dividend. Cardinal Health pays out 58.57% of its earnings as a dividend. Cardinal Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BUDZ or CAH?

    Weed quarterly revenues are --, which are smaller than Cardinal Health quarterly revenues of $54.9B. Weed's net income of -$440.5K is lower than Cardinal Health's net income of $506M. Notably, Weed's price-to-earnings ratio is 180.00x while Cardinal Health's PE ratio is 25.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.18x for Cardinal Health. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
    CAH
    Cardinal Health
    0.18x 25.18x $54.9B $506M
  • Which has Higher Returns BUDZ or COR?

    Cencora has a net margin of -- compared to Weed's net margin of 0.95%. Weed's return on equity of -- beat Cencora's return on equity of 183.42%.

    Company Gross Margin Earnings Per Share Invested Capital
    BUDZ
    Weed
    -- -$0.00 --
    COR
    Cencora
    4.06% $3.68 $9B
  • What do Analysts Say About BUDZ or COR?

    Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Cencora has an analysts' consensus of $321.50 which suggests that it could grow by 8.78%. Given that Cencora has higher upside potential than Weed, analysts believe Cencora is more attractive than Weed.

    Company Buy Ratings Hold Ratings Sell Ratings
    BUDZ
    Weed
    0 0 0
    COR
    Cencora
    10 5 0
  • Is BUDZ or COR More Risky?

    Weed has a beta of 0.654, which suggesting that the stock is 34.592% less volatile than S&P 500. In comparison Cencora has a beta of 0.576, suggesting its less volatile than the S&P 500 by 42.394%.

  • Which is a Better Dividend Stock BUDZ or COR?

    Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cencora offers a yield of 0.73% to investors and pays a quarterly dividend of $0.55 per share. Weed pays -- of its earnings as a dividend. Cencora pays out 27.58% of its earnings as a dividend. Cencora's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BUDZ or COR?

    Weed quarterly revenues are --, which are smaller than Cencora quarterly revenues of $75.5B. Weed's net income of -$440.5K is lower than Cencora's net income of $717.9M. Notably, Weed's price-to-earnings ratio is 180.00x while Cencora's PE ratio is 34.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.19x for Cencora. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
    COR
    Cencora
    0.19x 34.29x $75.5B $717.9M
  • Which has Higher Returns BUDZ or LAB?

    Standard BioTools has a net margin of -- compared to Weed's net margin of -63.81%. Weed's return on equity of -- beat Standard BioTools's return on equity of -26.52%.

    Company Gross Margin Earnings Per Share Invested Capital
    BUDZ
    Weed
    -- -$0.00 --
    LAB
    Standard BioTools
    48.39% -$0.07 $454.9M
  • What do Analysts Say About BUDZ or LAB?

    Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 126.19%. Given that Standard BioTools has higher upside potential than Weed, analysts believe Standard BioTools is more attractive than Weed.

    Company Buy Ratings Hold Ratings Sell Ratings
    BUDZ
    Weed
    0 0 0
    LAB
    Standard BioTools
    2 1 0
  • Is BUDZ or LAB More Risky?

    Weed has a beta of 0.654, which suggesting that the stock is 34.592% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.500, suggesting its more volatile than the S&P 500 by 50.042%.

  • Which is a Better Dividend Stock BUDZ or LAB?

    Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Weed pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BUDZ or LAB?

    Weed quarterly revenues are --, which are smaller than Standard BioTools quarterly revenues of $40.8M. Weed's net income of -$440.5K is higher than Standard BioTools's net income of -$26M. Notably, Weed's price-to-earnings ratio is 180.00x while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 2.32x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
    LAB
    Standard BioTools
    2.32x -- $40.8M -$26M
  • Which has Higher Returns BUDZ or MCK?

    McKesson has a net margin of -- compared to Weed's net margin of 1.39%. Weed's return on equity of -- beat McKesson's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BUDZ
    Weed
    -- -$0.00 --
    MCK
    McKesson
    4.01% $10.01 $4B
  • What do Analysts Say About BUDZ or MCK?

    Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand McKesson has an analysts' consensus of $758.57 which suggests that it could grow by 4.17%. Given that McKesson has higher upside potential than Weed, analysts believe McKesson is more attractive than Weed.

    Company Buy Ratings Hold Ratings Sell Ratings
    BUDZ
    Weed
    0 0 0
    MCK
    McKesson
    10 3 0
  • Is BUDZ or MCK More Risky?

    Weed has a beta of 0.654, which suggesting that the stock is 34.592% less volatile than S&P 500. In comparison McKesson has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.324%.

  • Which is a Better Dividend Stock BUDZ or MCK?

    Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. McKesson offers a yield of 0.39% to investors and pays a quarterly dividend of $0.71 per share. Weed pays -- of its earnings as a dividend. McKesson pays out 10.47% of its earnings as a dividend. McKesson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios BUDZ or MCK?

    Weed quarterly revenues are --, which are smaller than McKesson quarterly revenues of $90.8B. Weed's net income of -$440.5K is lower than McKesson's net income of $1.3B. Notably, Weed's price-to-earnings ratio is 180.00x while McKesson's PE ratio is 28.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 0.26x for McKesson. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
    MCK
    McKesson
    0.26x 28.19x $90.8B $1.3B
  • Which has Higher Returns BUDZ or PNPL?

    Pineapple has a net margin of -- compared to Weed's net margin of --. Weed's return on equity of -- beat Pineapple's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    BUDZ
    Weed
    -- -$0.00 --
    PNPL
    Pineapple
    -- -- --
  • What do Analysts Say About BUDZ or PNPL?

    Weed has a consensus price target of --, signalling downside risk potential of --. On the other hand Pineapple has an analysts' consensus of -- which suggests that it could fall by --. Given that Weed has higher upside potential than Pineapple, analysts believe Weed is more attractive than Pineapple.

    Company Buy Ratings Hold Ratings Sell Ratings
    BUDZ
    Weed
    0 0 0
    PNPL
    Pineapple
    0 0 0
  • Is BUDZ or PNPL More Risky?

    Weed has a beta of 0.654, which suggesting that the stock is 34.592% less volatile than S&P 500. In comparison Pineapple has a beta of 35.962, suggesting its more volatile than the S&P 500 by 3496.159%.

  • Which is a Better Dividend Stock BUDZ or PNPL?

    Weed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pineapple offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Weed pays -- of its earnings as a dividend. Pineapple pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios BUDZ or PNPL?

    Weed quarterly revenues are --, which are smaller than Pineapple quarterly revenues of --. Weed's net income of -$440.5K is higher than Pineapple's net income of --. Notably, Weed's price-to-earnings ratio is 180.00x while Pineapple's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Weed is -- versus 58.98x for Pineapple. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    BUDZ
    Weed
    -- 180.00x -- -$440.5K
    PNPL
    Pineapple
    58.98x -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock Overvalued?
Is Palantir Stock Overvalued?

By every traditional yardstick, including a price‑to‑sales well above 100,…

Is Gamestop’s Bitcoin Strategy Going To Succeed?
Is Gamestop’s Bitcoin Strategy Going To Succeed?

When GameStop (NYSE: GME) announced in Q1 that its board had…

How High Will Roku Stock Go?
How High Will Roku Stock Go?

Streaming software and hardware maker Roku (NASDAQ:ROKU) has seen its…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Sell
11
VEON alert for Jun 14

VEON [VEON] is down 18.57% over the past day.

Buy
74
DAVE alert for Jun 14

Dave [DAVE] is down 12.68% over the past day.

Buy
54
DAR alert for Jun 14

Darling Ingredients [DAR] is up 9.12% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock